Hematologic Oncology

December 17, 2020 - The FDA has approved rituximab-arrx, a biosimilar to rituximab, for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

Jorge E. Cortes, MD, shares advice for navigating among first- and second-generation TKIs in the frontline treatment of patients with chronic myeloid leukemia.

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.

December 15, 2020 - The FDA has granted a fast track designation to devimistat for the treatment of patients with acute myeloid leukemia.

TP53-mutant myelodysplastic syndromes and acute myeloid leukemia represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival.

Eunice Wang, MD, discusses preliminary findings from the ongoing KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of pevonedistat in myelodysplastic syndrome.

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.

CPX-351, when given at higher doses in induction cycles 1 and 2, significantly prolonged hematologic recovery in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

December 9, 2020 — The BCMA-targeted antibody-drug conjugate MEDI2228 showed promising clinical efficacy in patients with relapsed/refractory multiple myeloma, with triple-refractory disease experiencing maintained responses.

Yi Lin, MD, PhD, discusses​s updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

The antibody-drug conjugate TRPH-222 demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

December 8, 2020 — The antibody-drug conjugate brentuximab vedotin demonstrated high response rates with durability, as well as a tolerable safety profile among older patients with comorbid classical Hodgkin lymphoma.

Results reported from a group of patients with heavily pretreated multiple myeloma who were administered the combination of selinexor plus pomalidomide and low-dose dexamethasone produced positive responses and provided rationale for further investigation into the regimen.

December 8, 2020 - The combination of venetoclax and rituximab to retreat patients with relapsed/refractory chronic lymphocytic leukemia demonstrated a sustained time to next treatment benefit according to 5-year follow-up data of the MURANO study in a poster presentation at the 2020 ASH Meeting.

December 8, 2020 — Pevonedistat in combination with azacitidine improved overall survival and prolonged event-free survival compared with azacitidine monotherapy in patients with higher-risk myelodysplastic syndrome.

JAK2 and DNMT3A driver mutations can be acquired as early as in utero in patients with myeloproliferative neoplasms, demonstrating variable rates of clonal expansion and growth that influence the time to diagnosis.